Clinical trial
Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With…
NCT00303381 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00303381 |
|---|---|
| Title | Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis |
| Official title | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutaneously Administered IFN-beta-1a in the Treatment of Patients With Moderately Active Ulcerative Colitis |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Merck Serono International SA Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Interferon-beta-1a, 44 microgram, Placebo, 66 microgram |
| Enrollment | 194 |
| Start date | Dec 1, 2001 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Mar 16, 2006 |
| Last update posted | Aug 6, 2013 |
| Countries | Germany, Israel, Netherlands, Singapore, Sweden, Switzerland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: